Clinical trials: Diffuse Large Cell
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
RATIONALE: Monoclonal antibodies such as anti-cytotoxic T-lymphocyte-associated antigen-4 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00047164
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Diffuse Large B-cell Lymphoma
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed or refractory DLBCL.
- Trial name
- NCT03123393
- Testing
- TAK-659
- Where
- 41 sites in United States, Canada and 4 more
- Volunteers
- 49 people
- Sponsor
- Calithera Biosciences, Inc
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Background: People with primary diffuse large B-cell lymphoma of the central nervous system (CNS) and aggressive B-cell lymphomas with secondary CNS involvement have a poor prognosis.
- Trial name
- NCT05211336
- Testing
- Obinutuzumab, Prednisone, Lenalidomide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based…
- Trial name
- PRODIGY (NCT06227026)
- Testing
- Anti-CD19 CAR-T cells
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Utah
Diffuse Large B Cell Lymphoma
Biomarker Guided Treatment in DLBCL
This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma
- Trial name
- NCT04025593
- Testing
- Cyclophosphamide, Rituximab, Doxorubicin
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Ruijin Hospital
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly…
- Conditions
- Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04139304
- Testing
- Cyclophosphamide, Daratumumab, Doxorubicin
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- AIDS Malignancy Consortium
Diffuse Large B-Cell Lymphoma
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of zanubrutinib, rituximab and lenalidomide (ZR2) versus rituximab combined with low-dose CHOP (R-miniCHOP) in the treatment…
- Trial name
- NCT05179733
- Testing
- six courses of zanubrutinib, rituximab and lenalidomide, six courses of rituximab combined with low-dose CHOP
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma, Peripheral T Cell Lymphoma
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients
The purpose of this study is to evaluate the effectiveness of circulating DNA from peripheral blood for predicting the prognosis and relapse in DLBCL and PTCL patients.
- Trial name
- NCT03079947
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
DLBCL
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), to assess the change in ctDNA during treatment in order to…
- Trial name
- NCT03758989
- Testing
- Rituximab Prednisone, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Rochester
Lymphoma, Large B-Cell, Diffuse
Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients
Newly diagnosed diffuse large B cell lymphoma (DLBCL) patients who enter this study will receive baseline fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) scan at the time of initial staging.
- Trial name
- NCT01357733
- Testing
- Early interim FDG PET/CT after 1 cycle of R-CHOP
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- The Catholic University of Korea
Lymphoma
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009776
- Testing
- monoclonal antibody Lym-1, cyclosporine, paclitaxel
- Where
- United States
- Sponsor
- University of California, Davis
Lymphoma, Large B-Cell, Diffuse, Burkitt Lymphoma
A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma
This is a single center imaging study investigating the use of PET with 68Ga-citrate in patients with DLBCL or BCLU.
- Trial name
- NCT02776891
- Testing
- Gallium citrate
- Sponsor
- University of California, San Francisco
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Lymphoma, Large B-Cell, Diffuse
R-CHOP + GM-CSF for Previously Untreated LCL in Elderly
Patients will receive 6 to 8 cycles of R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone), with GM-CSF.
- Trial name
- NCT00582725
- Testing
- R-CHOP+GM-CSF
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Wisconsin, Madison
Lymphoid Malignancies, Multiple Myeloma
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest.
- Conditions
- Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Trial name
- PDX+Romi (NCT01947140)
- Testing
- Pralatrexate, Romidepsin
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Jennifer Amengual
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01787409
- Testing
- Cholecalciferol, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 565 people
- Sponsor
- Mayo Clinic
DLBCL, Diffuse Large B-Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the…
- Trial name
- NCT05139017
- Testing
- Zilovertamab vedotin, Rituximab, Gemcitabine
- Where
- 135 sites in United States, Argentina and 24 more
- Volunteers
- 290 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma (DLBCL), Double Expressor Lymphoma
Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma
This study is trying to explore the mechanism of R-CHOP regimen or tucidinostat plus R-CHOP (CR-CHOP) regimen in the treatment of BCL2/MYC protein double expressor lymphoma.
- Trial name
- DEL Biomarker (NCT06652152)
- Volunteers
- 400 people
- Sponsor
- Ruijin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.